Blarcamesine co-crystals for the manufacture of pharmaceutical dosage form
AssigneeEgis Gyogyszergyar Zrt.
InventorsZsuzsanna Szokol, Tamás Nagy, András Balázs Dancsó, Attila Virág, Regina Némethné Csillag, Károly Lozsi, Balázs Volk, László Szlávik
Life of this patent
Estimating the term…
Abstract
ZnCl2 co-crystal of racemic-(±)-blarcamesine hydrochloride of formula 2a, ZnCl2 co-crystal of (S)-(−)-blarcamesine hydrochloride of formula 2b and ZnCl2 co-crystal of (R)-(+)-blarcamesine hydrochloride of formula 2c, processes for preparation thereof and pharmaceutical preparation thereof and methods of treating neurodegenerative, neurodevelopmental diseases such as Alzheimer's disease, Parkinson's disease dementia and/or Rett syndrome.
Claims19
A method for treating a neurodegenerative or neurodevelopmental disease, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical dosage form comprising a therapeutically effective amount of a co-crystal of formula 2a, 2b or 2c and at least one therapeutically acceptable excipient,
- wherein the co-crystal of formula 2a is a racemic co-crystal of formula 2a consisting of one molecule of (R) and one molecule of(S) configuration of blarcamesine hydrochloride and one molecule of ZnCl2 per unit cell
- characterized by an XRPD pattern having peaks at 7.93;
- 9.66;
- 13.73;
- 15.77;
- 16.73;
- and 17.82° 2θ±0.2° 2θ;
- wherein the co-crystal of formula 2b is a co-crystal of formula 2b consisting of two molecules of(S) configuration of blarcamesine hydrochloride and one molecule of ZnCl2 per unit cell
- characterized by an XRPD pattern having peaks at 12.15;
- 12.85;
- 13.04;
- 13.24;
- 16.36;
- and 19.67° 2θ±0.2° 2θ;
- wherein the co-crystal of formula 2c is a co-crystal of formula 2c consisting of two molecules of (R) configuration of blarcamesine hydrochloride and one molecule of ZnCl2 per unit cell
- characterized by an XRPD pattern having peaks at 12.15;
- 12.85;
- 13.04;
- 13.24;
- 16.36;
- and 19.67° 2θ+0.2° 2θ;
- and
- wherein the neurodegenerative or neurodevelopmental disease to be treated is Alzheimer's disease, dementia due to Parkinson's disease, or Rett syndrome.
Dependencies are inferred from the claim text.